Phenomenal $BMSN D/D Orphan Drug BMSN**Why
Post# of 5066
BMSN**Why a quick FDA Orphan Drug Approval…
Regen BioPharma, a wholly-owned subsidiary of BMSN, has submitted an Investigational New Drug (IND) Application to the FDA nearly two weeks ago for approval of its HemaXellerate I™ stem cell drug to combat Aplastic Anemia. The post below explains why we should be hearing of FDA Approval for Regen BioPharma/BMSN to move forward with their clinical trials within the next 2 to 2 ½ weeks in my opinion: